Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECT WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Intervention/treatment:
PF-04383119 (TANEZUMAB)
Medical condition:
OSTEOARTHRITIS
Protocol code:
A4091056
Control number:
188803
Status:
Closed
Approved:
November 25, 2015
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02697773
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.
Phone:
1-800-718-1021
Sponsor
PFIZER CANADA INC

Locations

Ontario

Adachi Medicine Professional Corporation
Hamilton, Ontario, L8N 1Y2
Aggarwal and Associates Limited
Brampton, Ontario, L6T 0G1
Bluewater Clinical Research Group
Sarnia, Ontario, N7T 4X3
Dawson Road Medical Centre
Guelph, Ontario, N1H 1B1
K-W Musculoskeletal Research Inc.
Kitchener, Ontario, N2M 5N6
King Street Medical Clinic
Oshawa, Ontario, L1H 1G6
Malton Medical Centre
Mississauga, Ontario, L4V 1P1
Manna Research Inc. (Burlington south)
Burlington, Ontario, L7R 1A4
Rebecca Medical Associates
Oakville, Ontario, L6K 1J6
Western Center for Public Health and Family Medicine
London, Ontario, N6G 2M1

Quebec

Alpha Recherche Clinique
Québec, Quebec, G3K 2P8
Centre de recherche Saint-Louis
Québec, Quebec, G1W 4R4
Diex Recheche Montreal, Inc.
Montreal, Quebec, H2Y 1S1
Diex Recherche Quebec Inc.
Québec, Quebec, G1S 2L6
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1L 0H8
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.
Québec, Quebec, G1V 3M7
Recherche Clinique Sigma inc
Québec, Quebec, G1G 3Y8

Results

See the results from the trial NCT02697773. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?